Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
|Articles|January 1, 2008
Oncology NEWS International
- Oncology NEWS International Vol 17 No 1
- Volume 17
- Issue 1
Cellectar opens manufacturing facility for radiolabeled CLR1404
Cellectar opens manufacturing facility for radiolabeled CLR1404
Advertisement
MADISON, Wisconsin-Cellectar has opened its new $3.3 million radiopharmaceutical research, development, and manufacturing facility and headquarters in Madison. The facility allows Cellectar to manufacture and radiolabel its lead compound CLR1404, a phospholipid ether combined with 131Iodine, in compliance with Good Manufacturing Practices.
Articles in this issue
almost 19 years ago
New tobacco product alert: Camel Snus is on the loosealmost 19 years ago
Blueberry punch not quite a 'knock out' blowalmost 19 years ago
Texas voters listen to Lancealmost 19 years ago
High cost of breast MRI screening appears to be justifiedalmost 19 years ago
Broccoli Sprouts Extract Might Lower Bladder Cancer Riskalmost 19 years ago
Xeloda/Ixempra Effective in Resistant Triple-Negative Caalmost 19 years ago
Statins during RT may lower risk of prostate ca relapsealmost 19 years ago
Major policy issue lies behind ODAC's Avastin decisionAdvertisement
Related to this article
Heath Skinner, MD, PhD, discussed the 3 considerations that determine which new radiation oncology service lines his network chooses to build.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.
Heath Skinner, MD, PhD, discussed which new radiation oncology service lines community practices can implement, how leadership decides, and what launches require.
Jan Kitajewski, PhD, discusses how an ancestry-linked blood type may influence triple-negative breast cancer outcomes and clinical trial eligibility.
Black women die from breast cancer at rates 40% higher than white women — and are still missing from the trials that could help. Dr. Coral Omene on why.
A bispecific in biliary tract cancer, dostarlimab organ preservation in rectal cancer, and KRAS G12D data in pancreatic cancer stood out at ESMO 2026.
Advertisement
Advertisement
Trending on CancerNetwork
1
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
2
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
3
Recapping GI Cancer at ESMO 2026: Standout Data From Phase 1 to Phase 3
4
EU Approves T-DXd for HER2+ Early Breast Cancer With Residual Disease
5